MedTrace Logo

MMA Embolization for Refractory Chronic Migraine

NCT06735833 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Conditions

Interventions

DEVICE

Middle Meningeal Artery embolization

Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system

Sponsors & Collaborators

  • Cerenovus, Part of DePuy Synthes Products, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-23
Primary Completion
2028-12-25
Completion
2029-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06735833 on ClinicalTrials.gov